ASCO 2019

Area: Oncology

Location: Chicago, United States

Date: May 31 to June 4

Description:

American Society of Clinical Oncology.


Search in Scientific Content:
Date
Filters:
Immunother
4:09

Immunotherapies in Thymic Malignancies

Presenter: Heather A. Wakelee
Oncology : Lymphoma
Will There
2:57

Will There Ever Be Progress for Leptomeningeal Carcinomatosis: An Update on the Multidisciplinary Management in the Setting of Immuno-Oncology and Precision Medicine

Presenter: Priscilla Kaliopi Brastianos
Oncology : Lymphoma
Highlights
6:24

Highlights of prostate cancer research at ASCO2019

Presenter: Oliver Sartor
Oncology : Lymphoma
A randomiz
2:15

A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC)

Presenter: Jian-Ming Xu
Oncology : Lymphoma
Activity a
2:30

Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.

Presenter: Patrick Schoeffski
Oncology : Lymphoma
To Infinit
5:25

To Infinity and Beyond: The Future of Immunotherapy in Gynecologic Malignancies

Presenter: Oliver Dorigo
Oncology : Lymphoma
Hematologi...
8:54

Hematologic Malignancies—Plasma Cell Dyscrasia

Presenter: Noopur S. Raje
Oncology : Lymphoma
Sarcoma
5:60

Sarcoma

Presenter: Shreyaskumar Patel
Oncology : Lymphoma
ANNOUNCE:
4:55

ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS)

Presenter: William D. Tap
Oncology : Lymphoma
Targeting
8:34

Targeting Breast Cancer: Breaking the Code

Presenter: Julia R. White
Oncology : Lymphoma
Interim re
5:04

Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.

Presenter: Emmanuel S. Antonarakis
Oncology : Lymphoma
Should Imm
4:38

Should Immunotherapy Change the Practice for Esophageal and Gastric Cancer in the Near Future?

Presenter: Ramon Andrade De Mello
Oncology : Lymphoma
Nivolumab
2:58

Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.

Presenter: Arlene O. Siefker-Radtke
Oncology : Lymphoma
Identifica
7:08

Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.

Presenter: Donald Williams Parsons
Oncology : Lymphoma
Highlights
7:33

Highlights of the Metastatic Breast Cancer Session

Presenter: Sara M. Tolaney
Oncology : Lymphoma
Antiangiog
6:15

Antiangiogenic and Targeted Therapies With or Without Anti-PD1/Anti-PD-L1

Presenter: Guru Sonpavde
Oncology : Lymphoma

ESMO 2018

2018-10-19 - 2018-10-23
Munich, Germany

ASCO 2018

2018-06-01 - 2018-06-05
Chicago, United States

ECCO 2018

2018-02-14 - 2018-02-17
Vienna, Austria

SABCS 2017

2017-12-05 - 2017-12-09
San Antonio, United States

ESMO 2017

2017-09-08 - 2017-09-12
Madrid, Spain

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland

ASCO 2017

2017-06-02 - 2017-06-06
Chicago, United States

SABCS 2016

2016-12-06 - 2016-12-10
San Antonio, United States

ESMO 2016

2016-10-07 - 2016-10-11
Copenhagen, Denmark